Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.molimm.2007.09.010
Title: Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation
Authors: Lo, A.S.Y.
Taylor, J.R.
Farzaneh, F.
Kemeny, D.M. 
Dibb, N.J.
Maher, J.
Keywords: Adoptive immunotherapy
c-fms
CSF-1
T-cell
Issue Date: Mar-2008
Source: Lo, A.S.Y., Taylor, J.R., Farzaneh, F., Kemeny, D.M., Dibb, N.J., Maher, J. (2008-03). Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Molecular Immunology 45 (5) : 1276-1287. ScholarBank@NUS Repository. https://doi.org/10.1016/j.molimm.2007.09.010
Abstract: Aberrant growth factor production is a prevalent mechanism in tumourigenesis. If T-cells responded positively to a cancer-derived cytokine, this might result in selective enhancement of function within the tumour microenvironment. Here, we have chosen colony-stimulating factor-1 (CSF-1) as a candidate to test this concept. CSF-1 is greatly overproduced in many cancers but has no direct effects upon T-lymphocytes, which do not express the c-fms-encoded CSF-1 receptor. To confer CSF-1-responsiveness, we have expressed the human c-fms gene in immortalized and primary T-cells. Addition of soluble CSF-1 resulted in synergistic enhancement of IL-2-driven T-cell proliferation. CSF-1 also co-stimulated the production of interferon (IFN)-γ by activated T-cells. These effects required Y809 of the CSF-1R and activation of the Ras-MEK-MAP kinase cascade, but were independent of PI3K signalling. T-cells that express c-fms are also responsive to membrane-anchored CSF-1 (mCSF-1) which, unlike its soluble counterpart, could co-stimulate IL-2 production. CSF-1 promoted chemotaxis of c-fms-expressing primary human T-cells and greatly augmented proliferation mediated by a tumour-targeted chimeric antigen receptor, with preservation of tumour cytolytic activity. Taken together, these data establish that T-cells may be genetically modified to acquire responsiveness to CSF-1 and provide proof-of-principle for a novel strategy to enhance the effectiveness of adoptive T-cell immunotherapy. © 2007 Elsevier Ltd. All rights reserved.
Source Title: Molecular Immunology
URI: http://scholarbank.nus.edu.sg/handle/10635/132806
ISSN: 01615890
DOI: 10.1016/j.molimm.2007.09.010
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

14
checked on Apr 2, 2018

WEB OF SCIENCETM
Citations

12
checked on Apr 2, 2018

Page view(s)

7
checked on Mar 11, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.